Health Tech’s Two-Speed Capital Market

November’s edition finds a Health Tech and Life Sciences market with ample capital at the top end, but far more exacting requirements for companies outside the mega-round cohort. It also identifies regulation, reimbursement durability and proof of AI return on investment as the factors increasingly determining both speed to market and terms of capital.

Executive summary

Health Tech and Life Sciences capital markets remain active, but they are not broadly permissive. The past 6 to 12 months have produced very large financings in AI drug discovery, precision medicine, clinical AI, diagnostics and behavioural health, while buyers and investors have become more selective on operating quality, regulatory readiness and commercial evidence.

The defining feature is concentration. In Q1 2026, US digital-health companies raised $4.0 billion across 110 deals, but 12 rounds of $100 million or more absorbed 59% of that capital. Family offices are also participating materially in the upper end of the market, completing 27 healthcare and life-sciences deals in Q3 2026 alone. The implication is clear: there is no shortage of capital for companies that can demonstrate strategic importance and category leadership, but the financing environment for everyone else remains disciplined.

Where the capital is moving

Digital health raised $7.4 billion across 244 deals in H1 2026. The headline rounds show where conviction is strongest. Whoop raised $575 million; Verily raised $300 million; Talkiatry raised $210 million; eMed secured $200 million; Forus raised $160 million; and Grow Therapy raised $150 million. Clinical AI, mental health, chronic-care delivery and diagnostics are attracting funding where companies can show a credible route to clinical adoption and measurable value for providers, payers or consumers.

Biotech and AI-enabled drug discovery are attracting even larger cheques. Isomorphic Labs raised a $2.1 billion Series B in May 2026, led by Thrive Capital with Alphabet, GV, Temasek, CapitalG, MGX and the UK Sovereign AI Fund. This financing underlines the strategic premium assigned to platforms that may alter the economics and speed of drug development.

Other sizeable rounds reinforce the same pattern. Neko Health raised $700 million in July, Chai Discovery $400 million, Heidi Health $340 million, Ollin Biosciences $330 million, Enveda $311 million and OMass Therapeutics $310 million. Q3 rounds also included Anew Labs at $290 million, Encoded Therapeutics at $275 million, OpenEvidence and Precision Neuroscience at $250 million each, and Scan.com at $220 million.

The United States remains the dominant market, but capital is not entirely domestic. Anew Labs' $290 million financing from HongShan, formerly Sequoia China, points to continuing China-linked interest in selected health and biotech opportunities. Strategics are also active: Medtronic's planned $550 million acquisition of Scientia Vascular demonstrates ongoing demand for specialised medical-device capabilities, while Imperative Care raised $100 million in convertible notes from a syndicate including Elevage Medical Technologies, Perceptive Advisors, Catalio Capital and Bain Capital Life Sciences.

Pricing and structure

Valuation is bifurcated. Public cloud-software multiples have compressed to roughly 3.3x to 3.6x enterprise value to trailing revenue, but private M&A for mission-critical Health Tech platforms is achieving materially higher pricing. Mid-2026 market evidence places these assets at roughly 6x to 12x enterprise value to revenue and 15x to more than 20x enterprise value to EBITDA. Across the broader healthcare market, Q3 2026 median multiples were 14.25x TEV/EBITDA and 3.77x TEV/revenue.

These headline levels should not be mistaken for a general uplift. Premium valuations are reserved for proven, revenue-generating businesses with durable customer relationships, visible reimbursement, credible margins and manageable integration risk. Health-services buyers are especially focused on payer mix, execution readiness and reimbursement visibility. For AI-enabled assets, diligence now extends beyond technical capability to governance, regulatory readiness and tangible return on investment.

Deal structures are carrying more of the risk. H1 2026 Health Tech M&A recorded 322 transactions, approximately $24 billion of disclosed value and a median disclosed transaction value of about $33 million. Private equity represented roughly 34% of transactions. In life sciences, contingent consideration has moved from exception to standard practice: publicly disclosed CVRs increased from seven deals in 2024 to 27 in 2025, with some representing more than 70% of total deal value. Earn-outs appeared in 89% of private biopharma deals and 84% of private medtech deals in the mid-2023 to mid-2025 period.

For sellers, this means less upfront cash and more value tied to clinical, regulatory, revenue or product-development milestones. For buyers, it creates a mechanism to retain access to upside while reducing exposure to binary outcomes.

The angle nobody is covering

The less visible competitive divide is regulatory, not technological. In Europe, the convergence of the EU AI Act with Medical Device Regulation and In Vitro Diagnostic Regulation requirements is adding an estimated 18 to 24 months to software-as-a-medical-device certification timelines. This has direct implications for capital efficiency, commercial sequencing and competitive position.

By contrast, regulatory clarity around lower-risk wellness products in the United States offers a more direct route for certain AI-enabled consumer health products that do not require full medical classification. The result is a potential time-to-market advantage for US companies able to distinguish wellness products from regulated medical claims, while still building governance capable of supporting future clinical expansion.

This creates an underappreciated form of regulatory arbitrage. US-based teams with experience of global compliance may be able to develop products that launch more quickly at home while building a pathway for dual-regulated expansion. European founders are not excluded from opportunity, but they need to plan financing and commercial milestones around longer certification cycles. For investors, regulatory competence is becoming a source of defensibility rather than a back-office requirement.

What this means if you are raising

Companies should not position themselves simply as AI businesses. They need to show the economic and clinical mechanism by which AI improves a workflow, patient outcome, diagnostic decision or drug-development process. A financing narrative should directly address reimbursement, governance, data quality, regulatory classification, deployment timelines and evidence of return on investment.

Founders outside the mega-round cohort should not assume that concentration removes opportunity. It rewards focused propositions. Capital-efficient companies in under-followed segments, including compliant wellness platforms, clinically specific software and regulatory-savvy medtech, can differentiate through credible milestones rather than scale claims. In life sciences, management teams should prepare for milestone-heavy term sheets and model the operating consequences of delayed contingent proceeds.

What this means if you are deploying capital

The strongest opportunities sit where technical differentiation meets a clear route to adoption. In digital health, that means prioritising companies with evidence that providers, payers or consumers will pay for sustained use. In biotech, it means identifying platforms whose scientific promise can be translated into definable development milestones and structured accordingly.

Investors should underwrite regulatory timelines as carefully as market size. The European certification burden may create attractive entry points for teams with defensible clinical assets, but it also requires patient capital and realistic reserves. In the United States, lower-risk wellness pathways may support faster commercial testing, provided companies maintain discipline around claims and product classification.

The market is rewarding proof, not possibility. The winners will be businesses that can link AI capability to measurable value, manage regulatory complexity and finance their path without relying on an ever-larger next round.

Method note

These findings draw on the GI Network research desk's review of live market sources, dated November 2026. Sources reviewed include reported venture financings, family-office activity, M&A data, valuation analyses and legal-market commentary covering Health Tech, healthcare services, medtech and life sciences.